AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue SUPL. S1, 2002, Pages 21-30

  Adler Moore, Jill ^a   Proffitt, Richard T ^a,b  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; CHOLESTEROL; ERGOSTEROL; FLUCONAZOLE; LIPOSOME; MEGLUMINE ANTIMONATE; PHOSPHOLIPID; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CELL MEMBRANE; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FUNGAL MENINGITIS; FUNGICIDAL ACTIVITY; HISTOPLASMOSIS; KIDNEY INFECTION; LEISHMANIASIS; LUNG ASPERGILLOSIS; MOUSE; NEPHROTOXICITY; NONHUMAN; RAT; SOUTH AMERICAN BLASTOMYCOSIS; SYSTEMIC MYCOSIS;

EID: 0036178457     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.suppl_1.21     Document Type: Article

References (30)

1. Diffusion of univalent ions across the lamellae of swollen phospholipids
2. Comparative properties and methods of preparations of lipid vesicles (liposomes)
3. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol
4. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro
5. The formation of amphotericin B ion channels in lipid bilayers
6. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B
7. Determination of the relative toxicity of amphotericin B formulations: A red blood cell potassium release assay
8. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells
9. Comparative toxicities of Fungizone and AmBisome for cultured kidney cells and macrophages
10. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
11. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats
12. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
13. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs
14. AmBisome targeting to fungal infections
15. AmBisome: Long circulating formulation of Amphotericin B
16. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B
17. Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome
18. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
19. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis
20. Efficacy of intravenous AmBisome against coccidioidal meningitis in rabbits
21. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection
22. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis
23. Differences in efficacy and tissue drug concentrations following treatment of murine pulmonary aspergillosis with AmBisome (AMBI) or Abelcet
24. Treatment of murine candidiasis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)
25. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice
26. Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis
27. Efficacy of AmBisome (AMBI) loading dose regimens for the treatment of systemic candidiasis in immunosuppressed mice
28. Enhanced in vitro activity of AmBisome (AmBi) or Fungizone (Fz) combined with terbinafine (T) or azithromycin (Az) against fluconazole sensitive (FL-S) and resistant (FL-R) Candida species
29. AmBisome (AmB) or Fungizone (F) combined with terbinafine for the treatment of murine systemic candidiasis
30. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis